xanomeline

From Aaushi
Jump to navigation Jump to search

Indications

Adverse effects

Mechanism of action

More general terms

Component of

References

  1. Shekhar A et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008 Aug; 165:1033. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18593778
  2. Brannan SK, Sawchak S, Miller AC et al Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. N Engl J Med 2021; 384:717-726 Feb 25 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33626254 https://www.nejm.org/doi/full/10.1056/NEJMoa2017015B